CLINICAL TRIALS PROFILE FOR IMIPRAMINE HYDROCHLORIDE

All Clinical Trials for imipramine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000368 ↗	Treatment of Panic Disorder: Long Term Strategies	Completed	National Institute of Mental Health (NIMH)	Phase 3	1999-02-01	Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00000368 ↗	Treatment of Panic Disorder: Long Term Strategies	Completed	New York State Psychiatric Institute	Phase 3	1999-02-01	Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00000390 ↗	Antidepressant Treatment of AIDS Related Depression.	Completed	GEIGY Pharmaceuticals	Phase 2	1969-12-31	To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
NCT00000464 ↗	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1987-04-01	To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000464 ↗	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)	Completed	University of Washington	Phase 3	1987-04-01	To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000504 ↗	Cardiac Arrhythmia Pilot Study (CAPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1982-09-01	To compare the effectiveness of various drugs and drug combinations in suppressing complex ventricular arrhythmias, and to evaluate their safety.
NCT00000518 ↗	Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1985-07-01	To determine whether electrophysiologic study (EPS) or Holter monitoring (HM) was the better method for selecting effective long-term antiarrhythmic drug therapy in patients with sustained ventricular tachycardia, ventricular fibrillation, or an episode of aborted sudden death.

Clinical Trial Conditions for imipramine hydrochloride

Condition Name

Condition Name for imipramine hydrochloride
Intervention	Trials
Depression	9
Major Depression	4
Heart Diseases	4
Cardiovascular Diseases	4

Condition MeSH

Condition MeSH for imipramine hydrochloride
Intervention	Trials
Depression	16
Depressive Disorder	14
Depressive Disorder, Major	10
Disease	5

Clinical Trial Locations for imipramine hydrochloride

Trials by Country

Trials by Country for imipramine hydrochloride
Location	Trials
United States	23
Denmark	6
Egypt	4
Canada	3
Switzerland	3

Trials by US State

Trials by US State for imipramine hydrochloride
Location	Trials
Ohio	5
New York	5
Texas	2
Maryland	2
Alabama	2

Clinical Trial Progress for imipramine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for imipramine hydrochloride
Clinical Trial Phase	Trials
PHASE2	2
Phase 4	9
Phase 3	12

Clinical Trial Status

Clinical Trial Status for imipramine hydrochloride
Clinical Trial Phase	Trials
Completed	38
Recruiting	8
Not yet recruiting	4

Clinical Trial Sponsors for imipramine hydrochloride

Sponsor Name

Sponsor Name for imipramine hydrochloride
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	4
New York State Psychiatric Institute	4
Aalborg University	3

Sponsor Type

Sponsor Type for imipramine hydrochloride
Sponsor	Trials
Other	75
NIH	8
Industry	7

Imipramine hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Imipramine Hydrochloride: Clinical-Trials Update and Market Outlook

What is the current clinical-trials status of imipramine hydrochloride?

Imipramine hydrochloride is an established, off-patent tricyclic antidepressant (TCA) with long-standing clinical use. No robust, current portfolio-wide phase pipeline signal is available for “imipramine hydrochloride” as a brand-level drug-development program because the substance is widely marketed as a generic and is repeatedly used as a control arm comparator in newer antidepressant trials rather than a sponsor-driven lead asset.

What trial activity exists tends to be:

• Comparator use in antidepressant and related psychiatry studies rather than primary development
• Formulation- and access-focused studies in specific countries (often small, local, and not captured as a single centralized global program)
• Long-running observational studies tied to utilization patterns, safety, and adherence, which are not always tagged under “imipramine hydrochloride” as a distinct interventional product in global trial listings

Bottom line: the market is not being pulled forward by an ongoing, sponsor-centric phase program for imipramine hydrochloride. The drug’s clinical evidence base is mature and practice-driven, not pipeline-driven.

---

What is the market landscape for imipramine hydrochloride today?

Imipramine hydrochloride sits in a mature global antidepressant market dominated by:

• Generic TCAs for cost-sensitive settings
• Newer antidepressant classes (SSRIs/SNRIs and others) for clinical preference where tolerability and safety profiles matter

Market reality for an off-patent TCA:

• Price pressure is structurally high because multiple generics compete
• Demand persists in settings where TCAs are preferred due to lower acquisition cost or specific clinical positioning
• Formulary access drives throughput more than innovation

Key market drivers:

• Cost of therapy and reimbursement in public systems and emerging markets
• Clinical switching and augmentation practices for treatment-resistant depression and specific symptom clusters
• Physician familiarity with older antidepressants and dosing flexibility

Key market constraints:

• Adverse-event burden typical of TCAs (cardiac conduction risk, anticholinergic effects, sedation)
• Safety monitoring requirements that can reduce uptake in some health systems
• Competition from better-tolerated first-line options that reduce TCA share in many formularies

---

What does the projection look like for imipramine hydrochloride through the next 5 years?

Because the drug is off-patent and largely generic, forecasting hinges on:

1. Volume stability vs substitution
2. Net price erosion
3. Geographic mix (where TCAs retain share)

Most credible projection shape for a mature generic TCA:

• Units: modest decline or flat-to-low growth depending on region and formulary openness to TCAs
• Value: gradual contraction in many markets due to continued generic price pressure
• Steady demand pockets: countries and payer systems with strong cost-containment where TCAs remain reimbursed and used

Directional forecast (not point estimates)

Time window	Likely volume trend	Likely value trend	Primary driver
Near term (0-12 months)	Flat	Soft decline	Ongoing generic competition and substitution to newer agents
Mid term (1-3 years)	Slight down or flat	Moderate erosion	Ongoing price compression and formulary tightening
Longer term (3-5 years)	Flat-to-slight down	Slow decline	Persistent but restrained demand in cost-sensitive markets

Net:

• The drug’s market is expected to be stable in clinical relevance but pressured in economics.
• There is no credible catalyst (new patent-protected product cycle) implied by a sponsor-grade clinical pipeline, so upside is limited to geography and local reimbursement behavior.

---

Clinical-trial implications for stakeholders: what to watch

Even with limited development momentum, trial activity matters for market access and evidence reinforcement.

Watch categories (signals that move demand more than innovation):

• Comparative effectiveness studies where TCAs are benchmarked for specific depression subtypes or treatment-resistant populations
• Safety and tolerability data stratified by age, comorbidities, or dosing strategies
• Pragmatic trials focused on healthcare system implementation (switching, adherence, monitoring)
• Guideline updates that affect whether TCAs remain recommended as second- or later-line therapy in specific jurisdictions

---

How to frame investment and R&D strategy for imipramine hydrochloride

Given the absence of a patent-protected development pathway, the most actionable strategies tend to be commercial and operational rather than discovery-led.

Commercial levers

• Portfolio protection through niche positioning (indications and settings where TCAs remain used)
• Formulary and reimbursement contracting based on lowest cost per treated patient
• Channel strategy targeting institutions that still favor TCAs

R&D levers (where feasible)

• Formulation and delivery work only where it supports market access (bioavailability consistency, tolerability improvements, or adherence)
• Safety monitoring protocols that reduce payer friction
• Local clinical studies that strengthen payer and guideline adoption in specific countries

---

Key Takeaways

• Imipramine hydrochloride is an established, generic TCAs with clinical evidence anchored in historical use; current trial activity is more commonly comparative or observational, not a single sponsor-driven pipeline.
• The market is structurally price-competitive and demand is mostly sustained by cost-sensitive reimbursement and physician familiarity, with ongoing substitution pressure from newer antidepressants.
• The next 5-year outlook is best modeled as stable-to-slightly declining volume and slow value erosion, driven by generic price compression and formulary dynamics.
• Near-term upside is limited; the credible path is commercial execution and local market access, not new patent-led clinical development.

---

FAQs

1. Is imipramine hydrochloride currently in late-stage development?
   No evidence of a sponsor-led, global phase program is implied for imipramine hydrochloride as a development asset; trial activity is commonly comparator or observational in nature.

2. What most affects sales for a generic TCA like imipramine?
   Formulary access, reimbursement rules, and generic pricing versus substitution to newer antidepressant classes.

3. Does trial evidence still influence payer decisions for imipramine?
   Yes, but primarily through safety, comparative effectiveness, and pragmatic implementation findings that support policy and guideline adherence.

4. What are the main market risks?
   Continued price erosion, tighter safety scrutiny, and substitution away from TCAs in favor of better-tolerated antidepressants.

5. Where can demand remain resilient?
   Cost-sensitive healthcare systems and regions where TCAs retain guideline-supported positioning as later-line or treatment-resistant options.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Approval Reports and Labeling for antidepressants and tricyclic antidepressants (class information). FDA.
[2] World Health Organization (WHO). WHO Model List of Essential Medicines: Antidepressants. WHO.
[3] National Library of Medicine. ClinicalTrials.gov search results for “imipramine hydrochloride” (trial activity and status). ClinicalTrials.gov.
[4] OECD/IMS-style market context sources on generic antidepressant market dynamics (generic price erosion and market share shift) as reflected in industry summaries.